Connect Biopharma Holdings (CNTB) Enterprise Value (2020 - 2026)

Connect Biopharma Holdings (CNTB) has reported Enterprise Value for 7 consecutive years, with -$46.0 million the latest figure, recorded in Q1 2026.

• Quarterly Enterprise Value rose 45.2% year-over-year to -$46.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$46.0 million (up 45.2% YoY) and the FY2025 annual result came in at -$44.3 million, up 52.69% from the prior year.
• Enterprise Value slipped to -$46.0 million in Q1 2026 per CNTB's latest filing, from -$44.3 million in the prior quarter.
• Over the last five years, Enterprise Value for CNTB reached as high as -$44.3 million in Q4 2025 and fell as low as -$194.0 million in Q2 2022.
• A 5-year average of -$99.8 million and a median of -$93.7 million in 2024 frame the typical range for Enterprise Value.
• Annual changes were most pronounced in 2024 — Enterprise Value gained 16.24% — and 2025, when it soared 52.69%.
• Year by year, Enterprise Value stood at -$149.3 million in 2022, then rose by 20.74% to -$118.3 million in 2023, then advanced by 20.77% to -$93.7 million in 2024, then jumped by 52.69% to -$44.3 million in 2025, then declined by 3.81% to -$46.0 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered -$46.0 million, -$44.3 million, and -$54.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.